KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $133,344.00 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin L. Palleiko sold 14,400 shares of the business's stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $133,344.00. Following the sale, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

KalVista Pharmaceuticals Price Performance

KALV stock traded down $0.07 during trading on Wednesday, hitting $8.98. 165,768 shares of the company traded hands, compared to its average volume of 482,817. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.39 and a 1 year high of $16.88. The company has a market cap of $388.12 million, a PE ratio of -2.56 and a beta of 0.92. The stock's 50-day simple moving average is $11.10 and its 200 day simple moving average is $12.03.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. Research analysts expect that KalVista Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Vestal Point Capital LP increased its position in shares of KalVista Pharmaceuticals by 73.9% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company's stock valued at $46,320,000 after buying an additional 1,700,000 shares in the last quarter. Capital World Investors acquired a new stake in shares of KalVista Pharmaceuticals in the first quarter valued at about $17,370,000. Great Point Partners LLC purchased a new position in shares of KalVista Pharmaceuticals in the second quarter worth about $15,768,000. State Street Corp boosted its position in KalVista Pharmaceuticals by 68.1% during the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company's stock worth $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Finally, Emerald Advisers LLC boosted its position in KalVista Pharmaceuticals by 29.8% during the third quarter. Emerald Advisers LLC now owns 835,988 shares of the specialty pharmaceutical company's stock worth $9,681,000 after acquiring an additional 192,091 shares during the last quarter.

Wall Street Analysts Forecast Growth

KALV has been the subject of a number of research reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of KalVista Pharmaceuticals in a research report on Monday, September 9th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Monday, October 7th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, September 6th.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).